Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | PGK2 | P07205 | 1/20 | 0.32 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249852 | 0.84 | GABRA1 (0.40) | GABRA1GABRB2PDE4APDE4CPDE4D | |
| SCHEMBL14124548 | 0.75 | KDM1A (0.37) | GABRA1GABRB2PDE4APDE4CPDE4D | |
| SCHEMBL17429701 | 0.75 | CCR1 (0.43) | GABRA1GABRB2ALDH1A1KDM4EHPGD | |
| SCHEMBL5824067 | 0.75 | BACE1 (0.42) | GABRA1GABRB2 | |
| SCHEMBL8522029 | 0.75 | GABRA1 (0.34) | GABRA1GABRB2PDE4APDE4CPDE4D | |
| SCHEMBL10818509 | 0.75 | GABRA1 (0.42) | GABRA1GABRB2PGK1PGK2ALDH1A1 | |
| SCHEMBL8515582 | 0.73 | CYP4F2 (0.38) | GABRB2PDE4DPGK1PGK2KDM4E | |
| Ammonia Solution, Strong SCHEMBL4888956 | 0.72 | KDM4E (0.53) | KDM4E | |
| SCHEMBL7697012 | 0.72 | PDE4A (0.42) | PDE4APDE4CPDE4DALDH1A1KDM4E | |
| Formic Acid SCHEMBL28289297 | 0.72 | CYP3A4 (0.36) | GABRA1GABRB2PGK1PGK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119563-B2 | N-substituted azacycles | FMC CORPORATION (US) | 2012-02-21 | — | — | US | claimed |
| US-20090215821-A1 | N-Substituted Azacycles | FMC CORPORATION | 2009-08-27 | — | — | US | claimed |
| EP-1673083-A4 | N-SUBSTITUTED AZACYCLES | BAYER CROPSCIENCE AG (DE) | 2008-12-17 | — | — | EP | claimed |
| EP-1673083-A2 | N-SUBSTITUTED AZACYCLES | FMC CORPORATION (US) | 2006-06-28 | — | — | EP | claimed |
| WO-2005036961-A2 | N-SUBSTITUTED AZACYCLES | FMC CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| US-8119563-B2 | N-substituted azacycles | FMC CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090215821-A1 | N-Substituted Azacycles | FMC CORPORATION | 2009-08-27 | — | — | US | disclosed |
| EP-1673083-A4 | N-SUBSTITUTED AZACYCLES | BAYER CROPSCIENCE AG (DE) | 2008-12-17 | — | — | EP | disclosed |
| EP-1673083-A2 | N-SUBSTITUTED AZACYCLES | FMC CORPORATION (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005036961-A2 | N-SUBSTITUTED AZACYCLES | FMC CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215821-A1 | N-Substituted Azacycles | DDT, UQCRB, DNMT1 | GABRA1 2491/4885GABRB2 2426/4885PDE4A 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.